U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2012
608
Substance Class Protein
Created
by admin
on Wed Apr 02 08:16:27 GMT 2025
Edited
by admin
on Wed Apr 02 08:16:27 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
K16AIQ8CTM
Record Status FAILED
Record Version
  • Download
Related Record Type
ALTERNATIVE DEFINITION for [PERTUZUMAB]
Alternative Definition
Name Type Language
PERTUZUMAB
DASH   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
PERTUZUMAB (GENETICAL RECOMBINATION)
JAN  
Preferred Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Common Name English
RHUMAB-2C4
Code English
PERTUZUMAB [VANDF]
Common Name English
PERTUZUMAB [JAN]
Common Name English
RG-1273
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Common Name English
Pertuzumab [WHO-DD]
Common Name English
PERTUZUMAB [USAN]
Common Name English
PERJETA
Brand Name English
PERTUZUMAB [PURPLE BOOK CDER]
Common Name English
PERTUZUMAB [MART.]
Common Name English
RHUMAB2C4
Code English
RHUMAB 2C4
Code English
pertuzumab [INN]
Common Name English
PERTUZUMAB [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 284409
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
WHO-VATC QL01XC13
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
NCI_THESAURUS C155711
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
WHO-ATC L01XC13
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
NDF-RT N0000175661
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
FDA ORPHAN DRUG 400713
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
Code System Code Type Description
INN
8380
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
LACTMED
Pertuzumab
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
DRUG CENTRAL
4957
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
JAPANESE REVIEW
PERJETA
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY APPROVED JUNE 2013
SMS_ID
100000078567
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
MESH
C485206
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
DAILYMED
K16AIQ8CTM
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
ChEMBL
CHEMBL2007641
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
FDA UNII
K16AIQ8CTM
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
NCI_THESAURUS
C38692
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
RXCUI
1298944
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY RxNorm
CAS
380610-27-5
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
USAN
OO-59
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
EVMPD
SUB16455MIG
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
HSDB
8141
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
WIKIPEDIA
PERTUZUMAB
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
MERCK INDEX
m8568
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB06366
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
IUPHAR
5046
Created by admin on Wed Apr 02 08:16:27 GMT 2025 , Edited by admin on Wed Apr 02 08:16:27 GMT 2025
PRIMARY
From To
1_22 1_96
1_146 1_202
1_222 3_214
1_228 2_228
1_231 2_231
1_263 1_323
1_369 1_427
2_22 2_96
2_146 2_202
2_222 4_214
2_263 2_323
2_369 2_427
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
Related Record Type Details
SYSA-1901 (pertuzumab biosimilar)
BIOSIMILAR -> PARENT
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2
TARGET -> INHIBITOR
HER dimerization inhibitor
BINDING
PERTUZUMAB-ZZXF
SUB_CONCEPT->SUBSTANCE
PERTUZUMAB ZUVOTOLIMOD
DERIVATIVE -> PARENT
PERTUZUMAB DEFEROXAMINE ZIRCONIUM ZR-89
LABELED -> NON-LABELED
SYSA-1901 (pertuzumab biosimilar)
SUB_CONCEPT->SUBSTANCE
Cetuximab
INHIBITOR -> TARGET
Related Record Type Details
PERTUZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:SEQUENCE(CALCULATED) CHEMICAL
Volume of Distribution PHARMACOKINETIC
Molecular Formula CHEMICAL
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966